دورية أكاديمية
Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses?
| العنوان: | Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses? |
|---|---|
| المؤلفون: | Menzler J; Institute for Health and Pharmacoeconomics, Muenchen 81739, Germany., Neubauer A; Institute for Health and Pharmacoeconomics, Muenchen 81739, Germany.; Private Practice Ophthalmology, Muenchen 81739, Germany., Ziemssen F; Center for Ophthalmology, Eberhard-Karls University, Tuebingen 72076, Germany. |
| المصدر: | International journal of ophthalmology [Int J Ophthalmol] 2019 Feb 18; Vol. 12 (2), pp. 342-345. Date of Electronic Publication: 2019 Feb 18 (Print Publication: 2019). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Press of International Journal of Ophthalmology Country of Publication: China NLM ID: 101553860 Publication Model: eCollection Cited Medium: Print ISSN: 2222-3959 (Print) Linking ISSN: 22223959 NLM ISO Abbreviation: Int J Ophthalmol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Xi'an, China : Press of International Journal of Ophthalmology |
| مستخلص: | We inquired the impact of reduced therapy discontinuation in diabetic macular edema (DME) on physician's revenue considering anti-vascular endothelial growth factor (VEGF) monotherapy and its combination with Navilas treatment. Data were collected on injection frequency, treatment discontinuation and reimbursement fees for DME treatment with anti-VEGF compared to anti-VEGF in combination with navigated laser. Based on these data an economic model was built to compare physicians revenue over a 5y period using either therapy for 4 European countries and the USA. Due to patients' higher therapy adherence, physicians using navigated laser therapy with anti-VEGF generate similar or higher revenues compared to VEGF monotherapy in all analyzed countries. The use of Navilas decreases the patient's injection burden at the same clinical outcome, while the physician's revenue remained stable or increased. Therewith, therapy discontinuation in DME can be reduced using the combination therapy with Navilas. |
| References: | Clin Ther. 2001 Aug;23(8):1296-310. (PMID: 11558866) Br J Ophthalmol. 2014 Aug;98(8):1036-41. (PMID: 24723616) PLoS One. 2014 Dec 26;9(12):e113981. (PMID: 25541960) N Engl J Med. 2015 Mar 26;372(13):1193-203. (PMID: 25692915) Retina. 2015 Sep;35(9):1743-9. (PMID: 25901835) Asia Pac J Ophthalmol (Phila). 2013 Sep-Oct;2(5):295-9. (PMID: 26107032) JAMA Ophthalmol. 2016 Jan;134(1):21-9. (PMID: 26513684) Br J Ophthalmol. 2017 Mar;101(3):353-359. (PMID: 27215744) Clin Ophthalmol. 2016 May 24;10:939-46. (PMID: 27307696) Ophthalmology. 2017 Jan;124(1):74-81. (PMID: 27836430) BMC Ophthalmol. 2017 Jan 19;17(1):7. (PMID: 28103831) Clin Ophthalmol. 2017 Feb 21;11:393-401. (PMID: 28260851) Dev Ophthalmol. 2017;60:165-174. (PMID: 28427075) Ophthalmology. 2018 May;125(5):683-690. (PMID: 29336896) Clin Ophthalmol. 2017 Dec 20;12:13-20. (PMID: 29339917) |
| فهرسة مساهمة: | Keywords: Navilas; adherence; cost-effectiveness; diabetic macular edema; injection burden; laser therapy |
| تواريخ الأحداث: | Date Created: 20190228 Latest Revision: 20201001 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC6376239 |
| DOI: | 10.18240/ijo.2019.02.24 |
| PMID: | 30809494 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!